High expression of MICA and NKG2D is strongly linked to tumor immunosurveillance (Groh et al., 2002; Choy and Phipps, 2010) while low levels of MICA are associated with a poor prognosis in patients receiving aggressive chemotherapy for CRC (Chen and Gyllensten, 2014). The gene discussed is KLRK1; the disease is colorectal carcinoma.